Non-adjuvant RSV Vaccine in Older Adults

Author(s):

Carrie Koenigsfeld, PharmD, FAPhA

An RSV medical expert provides an overview of the RENOIR trial, which investigated the efficacy and safety of an adjuvanted RSV vaccine in adults aged 60 years and older, focusing on the vaccine's effectiveness in preventing RSV-associated lower respiratory tract infections and presenting other crucial findings from the study.

EP: 1.Adjuvant RSV Vaccine in Older Adults

Now Viewing

EP: 2.Non-adjuvant RSV Vaccine in Older Adults

EP: 3.RSV Vaccine Efficacy in Pregnancy

EP: 4.Who Not to Vaccinate Against RSV

EP: 5.RSV Vaccine Administration Timing and Errors

EP: 6.Role of the Pharmacist in Vaccinating Against RSV

EP: 7.What is RSV?

EP: 8.Lasting Impacts of RSV

EP: 9.Limiting Transmission of RSV

EP: 10.Preparation of RSV Vaccines

EP: 11.Role of Pharmacists in Improving Vaccine Uptake

EP: 12.Pharmacists Enhancing RSV Care

The RENOIR trial studied the safety and efficacy of non-adjuvanted vaccine in adults aged 60 years or older. What interim results were significant from this trial leading to the indication of the vaccine for this population?
1. Efficacy at preventing RSV-associated lower respiratory tract infections
2. Adverse effects
3. Trial limitations